KalVista Pharmaceuticals, Inc. (KALV)
20.84
+0.56
(+2.74%)
USD |
NASDAQ |
Apr 15, 16:00
20.84
0.00 (0.00%)
After-Hours: 20:00
KalVista Pharmaceuticals Research and Development Expense (Annual) : 55.64M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Intellia Therapeutics, Inc. | 379.09M |
| Recursion Pharmaceuticals, Inc. | 425.27M |
| Tango Therapeutics, Inc. | 129.88M |
| Modular Medical, Inc. | 14.70M |
| Iovance Biotherapeutics, Inc. | 300.27M |